Drug design from the cryptic inhibitor envelope.

Published

Journal Article

Conformational dynamics plays an important role in enzyme catalysis, allosteric regulation of protein functions and assembly of macromolecular complexes. Despite these well-established roles, such information has yet to be exploited for drug design. Here we show by nuclear magnetic resonance spectroscopy that inhibitors of LpxC--an essential enzyme of the lipid A biosynthetic pathway in Gram-negative bacteria and a validated novel antibiotic target--access alternative, minor population states in solution in addition to the ligand conformation observed in crystal structures. These conformations collectively delineate an inhibitor envelope that is invisible to crystallography, but is dynamically accessible by small molecules in solution. Drug design exploiting such a hidden inhibitor envelope has led to the development of potent antibiotics with inhibition constants in the single-digit picomolar range. The principle of the cryptic inhibitor envelope approach may be broadly applicable to other lead optimization campaigns to yield improved therapeutics.

Full Text

Duke Authors

Cited Authors

  • Lee, C-J; Liang, X; Wu, Q; Najeeb, J; Zhao, J; Gopalaswamy, R; Titecat, M; Sebbane, F; Lemaitre, N; Toone, EJ; Zhou, P

Published Date

  • February 25, 2016

Published In

Volume / Issue

  • 7 /

Start / End Page

  • 10638 -

PubMed ID

  • 26912110

Pubmed Central ID

  • 26912110

Electronic International Standard Serial Number (EISSN)

  • 2041-1723

International Standard Serial Number (ISSN)

  • 2041-1723

Digital Object Identifier (DOI)

  • 10.1038/ncomms10638

Language

  • eng